Kenneth A. JanikPartnerNelson MullinsWebsitewww.nelsonmullins.com/Organization ProfileFull ProfileConnectEmail803-255-9460 Professional Biography Ken practices in the areas of executive compensation, taxation, ERISA and employee benefits, and corporate law. He is certified by the Supreme Court of South Carolina as a tax specialist. More Legal and Business Bylines From Kenneth A. Janik Telehealth Coverage Reinstated for HDHP/HSAs Effective April 1, 2022 - (Posted On Tuesday, March 29, 2022) UPDATE: California Releases Guidance and Required Notices for 2022 COVID-19 Supplemental Paid Sick Leave - (Posted On Monday, February 21, 2022) Reminder – Medicare Part D Notices due October 15, 2021 - (Posted On Wednesday, October 13, 2021) Utilizing Wellness Programs to Incentivize COVID-19 Vaccinations - (Posted On Wednesday, September 01, 2021) IRS Updates EPCRS Correction Program for Qualified Retirement Plans - (Posted On Wednesday, July 28, 2021) Current Legal Analysis UPC Court of Appeal Rules on Suspending First Instance Enforcement, Managing Director Liability by: Lisa Nassi FINRA Facts and Trends: November 2024 by: Joshua Klein , Russell W. Gallaro Dividing Cryptocurrency in a New Jersey Divorce: What You Need to Know by: Louis M. Ragone New Pay Transparency Law to Go into Effect Beginning June 1, 2025 by: Ari G. Burd , Jeri L. Abrams BREAKING: Massachusetts Passes Clean Energy Bill Streamlining Permitting Process for Battery Energy Storage Systems by: Andrew O. Kaplan , Daniel J. Bailey Should Law Schools Teach The California Constitution? by: Keith Paul Bishop Upcoming Events Nov 21 2024 Third-Party Litigation Funding through a Transatlantic Lens Nov 21 2024 CC&Rs and Easements for Mixed-Use Projects: Best Practices for Developers Nov 21 2024 AI Patent Eligibility: Processing the USPTO's New Guidance Nov 21 2024 Update of 2024 California Employment Law Cases Nov 25 2024 2024 Election: Impact on the Health Care Legal and Policy Landscape Webinar Dec 4 2024 TSCA 30/30 - December 4, 2024 Dec 4 2024 GLP-1 Drugs: What's Next after FDA's Resolution of Drug Shortages Dec 4 2024 REACH 30/30 - 04 December 2024 Print
